Side-by-side · Research reference
CartalaxvsPTD-DBM
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-MechanisticHUMAN-REVIEWED10/32 cited
BAnimal-StrongHUMAN-REVIEWED10/40 cited
Cartalax
Bioregulator Peptide · Khavinson School
SQ · Protocol Unspecified
01Mechanism of Action
Parameter
Cartalax
PTD-DBM
Primary target
Mesenchymal stem cells (MSCs) undergoing chondrogenic differentiationLinkova 2023
CXXC5–Dishevelled protein-protein interaction
Pathway
Modulation of WNT, ERK-p38, and Smad 1/5/8 signaling pathwaysLinkova 2023
Downstream effect
Upregulation of chondrogenic genes (COL2, SOX9, ACAN); increased bone mineral density; osteoprotective effects in ovariectomy-induced osteoporosisLinkova 2023Povorozniuk 2007
Activated Wnt/β-catenin signaling promotes hair follicle regeneration, dermal stem cell activation, reduced myofibroblast differentiation
Feedback intact?
—
Not applicable — pathway derepression rather than receptor agonism
Origin
Derived from cartilaginous tissue extracts (Khavinson bioregulator methodology)Povorozniuk 2007
Engineered fusion: cell-penetrating PTD sequence + Dvl-binding motif targeting CXXC5
Antibody development
—
—
02Dosage Protocols
Parameter
Cartalax
PTD-DBM
Animal model dose
Unspecified (cartilaginous tissue extract protocol)
Rat study; extract preparation details not indexed in available abstracts.
—
Human dosing
Not established in PubMed-indexed literature
Russian-tradition protocols exist but lack peer-reviewed Western validation.
—
Evidence basis
Animal mechanistic studies only
Animal models only (mice)
Wound healing protocol
—
Hydrogel patch delivery (concentration not disclosed)
Pyrogallol-HA patch, murine model.
Hair regeneration protocol
—
Topical application (exact dose not disclosed)
Wound-induced hair neogenesis model, mice.
Co-administration
—
Valproic acid (GSK-3β inhibitor) for wound healing synergyLee 2023
Combined treatment maximized scar reduction.
Human translation
—
No published human studies
03Metabolic / Fat Loss Evidence
Parameter
Cartalax
PTD-DBM
Fat loss evidence
None — primary target is cartilage and bone tissue, not adipose
—
04Side Effects & Safety
Parameter
Cartalax
PTD-DBM
Documented adverse effects
None reported in indexed animal studies
—
Human safety data
Not available in PubMed-indexed literature
—
Reported adverse events
—
None reported in animal studies
Wnt pathway activation risks
—
Theoretical risk of aberrant proliferation; Wnt dysregulation linked to tumorigenesis
Long-term safety
—
Unknown — no chronic dosing or human data
Delivery vehicle effects
—
HA-PG hydrogel well-tolerated in mice; human translation pending
Absolute Contraindications
Cartalax
- ·Unknown due to lack of human clinical trial data
PTD-DBM
- ·Active malignancy (Wnt pathway involvement in tumorigenesis)
- ·Pregnancy / lactation (no safety data)
Relative Contraindications
Cartalax
- ·Active malignancy (theoretical; peptide bioregulators may influence cell proliferation pathways)
PTD-DBM
- ·History of Wnt-driven tumors
- ·Skin lesions with uncertain malignant potential
05Administration Protocol
Parameter
Cartalax
PTD-DBM
1. Route
Subcutaneous injection typical for Khavinson bioregulators; specific protocols not detailed in indexed literature.
Pyrogallol-functionalized hyaluronic acid (HA-PG) hydrogel patch loaded with PTD-DBM peptide, applied directly to wound bed. Adhesive hydrogel provides sustained release over multiple days.Lee 2023
2. Frequency
Russian-tradition protocols often employ 10-day cycles; precise frequency unspecified in available abstracts.
Topical application to scalp or wound site. Precise formulation not disclosed; studies used Cxxc5 knockout or direct peptide application in wound-induced hair neogenesis models.Ryu 2023
3. Storage
Lyophilised peptide bioregulators typically stored at 2–8 °C, light-protected. Reconstitution details not indexed.
PTD-DBM + valproic acid (GSK-3β inhibitor) in HA-PG patch showed synergistic effect on scar reduction and regenerative wound healing. VPA enhances Wnt pathway activation downstream.Lee 2023
4. Storage & Handling
—
Not disclosed in available literature. Peptide stability and storage conditions not published.